Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $84

Benzinga Newsdesk www.benzinga.com Negative 93.5%

Neg 93.5% Neu 0% Pos 0%

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and lowers the price target from $87 to $84.